Compare Stocks: PLRX, FATE, YDES, and PYXS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FATE Fate Therapeutics	$2.53 +0.4%	$2.55	$0.94 ▼ $3.23	$303.15M	2.54	1.24 million shs	4.19 million shs
PLRX Pliant Therapeutics	$1.11 -1.8%	$1.11	$1.02 ▼ $1.95	$68.73M	1.27	374,925 shs	438,690 shs
PYXS Pyxis Oncology	$3.33 -2.3%	$3.10	$1.03 ▼ $5.55	$277.75M	1.34	895,960 shs	563,433 shs
YDES YD Bio	$3.19 -1.5%	$3.16	$1.70 ▼ $22.00	$225.82M	N/A	413,026 shs	535,518 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FATE Fate Therapeutics	0.00%	+9.52%	+3.27%	+21.93%	+166.32%
PLRX Pliant Therapeutics	0.00%	-5.13%	-0.89%	-4.31%	-23.97%
PYXS Pyxis Oncology	0.00%	+3.74%	+6.73%	+64.04%	+50.68%
YDES YD Bio	0.00%	-20.25%	-33.40%	+31.82%	+318,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FATE Fate Therapeutics	$2.53 +0.4%	$2.55	$0.94 ▼ $3.23	$303.15M	2.54	1.24 million shs	4.19 million shs
PLRX Pliant Therapeutics	$1.11 -1.8%	$1.11	$1.02 ▼ $1.95	$68.73M	1.27	374,925 shs	438,690 shs
PYXS Pyxis Oncology	$3.33 -2.3%	$3.10	$1.03 ▼ $5.55	$277.75M	1.34	895,960 shs	563,433 shs
YDES YD Bio	$3.19 -1.5%	$3.16	$1.70 ▼ $22.00	$225.82M	N/A	413,026 shs	535,518 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FATE Fate Therapeutics	0.00%	+9.52%	+3.27%	+21.93%	+166.32%
PLRX Pliant Therapeutics	0.00%	-5.13%	-0.89%	-4.31%	-23.97%
PYXS Pyxis Oncology	0.00%	+3.74%	+6.73%	+64.04%	+50.68%
YDES YD Bio	0.00%	-20.25%	-33.40%	+31.82%	+318,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FATE Fate Therapeutics	2.38	Hold	$5.90	133.20% Upside
PLRX Pliant Therapeutics	1.75	Reduce	$3.00	170.27% Upside
PYXS Pyxis Oncology	2.70	Moderate Buy	$8.75	162.76% Upside
YDES YD Bio	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest PLRX, FATE, YDES, and PYXS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	PYXS Pyxis Oncology	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$6.00 ➝ $8.00
9/10/2026	PYXS Pyxis Oncology	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$7.00 ➝ $8.00
9/9/2026	PYXS Pyxis Oncology	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$12.00 ➝ $19.00
8/18/2026	PYXS Pyxis Oncology	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$7.00
8/14/2026	FATE Fate Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$6.00 ➝ $8.00
8/14/2026	FATE Fate Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$2.50 ➝ $3.50
8/14/2026	FATE Fate Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$7.00
8/7/2026	FATE Fate Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/3/2026	PYXS Pyxis Oncology	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$12.00
8/3/2026	PYXS Pyxis Oncology	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$12.00
7/17/2026	PLRX Pliant Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FATE Fate Therapeutics	$6.65M	45.59	N/A	N/A	$1.80 per share	1.41
PLRX Pliant Therapeutics	$1.58M	43.50	N/A	N/A	$2.95 per share	0.38
PYXS Pyxis Oncology	$13.86M	20.04	N/A	N/A	$0.86 per share	3.87
YDES YD Bio	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FATE Fate Therapeutics	-$136.32M	-$1.05	N/A	N/A	N/A	-1,941.09%	-65.08%	-41.73%	10/29/2026 (Estimated)
PLRX Pliant Therapeutics	-$149.34M	-$1.49	N/A	N/A	N/A	N/A	-52.17%	-40.46%	11/5/2026 (Estimated)
PYXS Pyxis Oncology	-$79.62M	-$1.41	N/A	N/A	N/A	N/A	-215.23%	-112.19%	11/2/2026 (Estimated)
YDES YD Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest PLRX, FATE, YDES, and PYXS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/1/2026	Q2 2026	YDES YD Bio	N/A	$0.05	N/A	$0.0450	N/A	$0.42 million
8/13/2026	Q2 2026	FATE Fate Therapeutics	-$0.2536	-$0.25	+$0.0036	-$0.25	$1.94 million	$2.08 million
8/13/2026	Q2 2026	PYXS Pyxis Oncology	-$0.35	-$0.40	-$0.05	-$0.40	$0.03 million	N/A
8/11/2026	Q2 2026	PLRX Pliant Therapeutics	-$0.3418	-$0.36	-$0.0182	-$0.36	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
PLRX Pliant Therapeutics	N/A	N/A	N/A	N/A	N/A
PYXS Pyxis Oncology	N/A	N/A	N/A	N/A	N/A
YDES YD Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FATE Fate Therapeutics	N/A	4.85	4.85
PLRX Pliant Therapeutics	N/A	9.90	9.90
PYXS Pyxis Oncology	N/A	1.34	1.34
YDES YD Bio	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FATE Fate Therapeutics	97.54%
PLRX Pliant Therapeutics	97.30%
PYXS Pyxis Oncology	39.07%
YDES YD Bio	N/A

Insider Ownership

Company	Insider Ownership
FATE Fate Therapeutics	4.74%
PLRX Pliant Therapeutics	8.74%
PYXS Pyxis Oncology	5.70%
YDES YD Bio	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FATE Fate Therapeutics	161	119.82 million	114.14 million	Optionable
PLRX Pliant Therapeutics	49	61.92 million	56.51 million	Optionable
PYXS Pyxis Oncology	56	83.41 million	78.65 million	Optionable
YDES YD Bio	15	70.79 million	N/A	N/A

PLRX, FATE, YDES, and PYXS Headlines

Recent News About These Companies

YD Bio (NASDAQ:YDES) CEO Ethan Phd Shen Purchases 3,100 Shares of Stock

September 11, 2026 | insidertrades.com

YD Bio (NASDAQ:YDES) Stock Price Down 7.8% - Time to Sell?

September 10, 2026 | americanbankingnews.com

中概股跌幅榜前十，YD Bio Limited(YDES.US)跌22.71%，房多多(DUO.US)跌20.85%

September 1, 2026 | finet.hkF

YD Bio Ltd (YDES)

September 1, 2026 | finance.yahoo.com

YD Bio Files First-Half 2026 Results, Reports Improved Equity Position

September 1, 2026 | tipranks.com

YD Bio Limited Reports First-Half 2026 Financial Results, 315% Revenue Growth and Net Income of $6.7 Million

August 31, 2026 | quiverquant.comQ

YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

August 31, 2026 | globenewswire.com

YDES - YD Bio Limited

August 26, 2026 | seekingalpha.com

Yd Bio Limited publie un article de revue évalué par les pairs dans Nutrients et lance deux produits nutraceutiques à Taïwan

August 26, 2026 | zonebourse.comZ

YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

August 25, 2026 | globenewswire.com

YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare ...

August 11, 2026 | markets.businessinsider.com

YD Bio Launches Physician-Led Nutraceuticals in Taiwan to Build Consumer Health Ecosystem

August 11, 2026 | tipranks.com

YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research

August 4, 2026 | markets.businessinsider.com

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

July 28, 2026 | finance.yahoo.com

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

July 24, 2026 | markets.businessinsider.com

YD Bio Limited

July 15, 2026 | cnn.com

YD Bio Limited Ordinary Shares (YDES) Insider Activity

July 14, 2026 | nasdaq.com

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

July 2, 2026 | globenewswire.com

YD Bio Ltd.

June 25, 2026 | barrons.com

Yd Bio

June 25, 2026 | fool.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX, FATE, YDES, and PYXS Company Descriptions

Fate Therapeutics NASDAQ:FATE

$2.53 +0.01 (+0.40%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.59 +0.06 (+2.21%)

As of 09/18/2026 07:30 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Pliant Therapeutics NASDAQ:PLRX

$1.11 -0.02 (-1.77%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.12 +0.00 (+0.45%)

As of 09/18/2026 04:10 PM Eastern

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Pyxis Oncology NASDAQ:PYXS

$3.33 -0.08 (-2.35%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.40 +0.07 (+2.16%)

As of 09/18/2026 07:56 PM Eastern

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

YD Bio NASDAQ:YDES

$3.19 -0.05 (-1.54%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.25 +0.06 (+1.88%)

As of 09/18/2026 07:55 PM Eastern

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PLRX, FATE, YDES, and PYXS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PLRX, FATE, YDES, and PYXS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PLRX, FATE, YDES, and PYXS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX, FATE, YDES, and PYXS Company Descriptions

Fate Therapeutics NASDAQ:FATE

Pliant Therapeutics NASDAQ:PLRX

Pyxis Oncology NASDAQ:PYXS

YD Bio NASDAQ:YDES

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PLRX, FATE, YDES, and PYXS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PLRX, FATE, YDES, and PYXS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PLRX, FATE, YDES, and PYXS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX, FATE, YDES, and PYXS Company Descriptions

Fate Therapeutics NASDAQ:FATE

Pliant Therapeutics NASDAQ:PLRX

Pyxis Oncology NASDAQ:PYXS

YD Bio NASDAQ:YDES

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools